{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-029912","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.715750+00:00","generated_at":"2026-05-15T09:53:43.532798+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MetaVia (MTVA) IRB approves Phase 1 Part 3 trial of DA-1726 at 48 mg and 64 mg doses","bullets":["Phase 1 Part 3 trial will enroll 40 obese adults across two 16-week titration cohorts randomized 4:1.","Part 3A tests one-step titration to 48 mg; Part 3B two-step to 64 mg; primary endpoints safety/tolerability.","Initial dosing expected April 2026; data readout expected Q4 2026.","CEO cites prior 48 mg cohort results: ~9% weight loss, improved glycemic control, favorable safety profile."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-029912","json":"https://secwatch.observer/filing/0001104659-26-029912.json","markdown":"https://secwatch.observer/filing/0001104659-26-029912.md","text":"https://secwatch.observer/filing/0001104659-26-029912.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926029912/0001104659-26-029912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926029912/mtva-20260318x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:53:43.532798+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}